Your browser is no longer supported. Please, upgrade your browser.
RARX Ra Pharmaceuticals, Inc. daily Stock Chart
RARX [NASD]
Ra Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.99 Insider Own4.47% Shs Outstand47.30M Perf Week0.43%
Market Cap2.23B Forward P/E- EPS next Y-2.49 Insider Trans-5.87% Shs Float45.23M Perf Month1.07%
Income-82.10M PEG- EPS next Q-0.63 Inst Own92.71% Short Float9.07% Perf Quarter91.02%
Sales5.50M P/S405.92 EPS this Y14.60% Inst Trans14.41% Short Ratio3.54 Perf Half Y107.56%
Book/sh6.42 P/B7.35 EPS next Y-14.70% ROA-35.60% Target Price48.00 Perf Year186.41%
Cash/sh6.19 P/C7.63 EPS next 5Y- ROE-37.90% 52W Range15.23 - 47.48 Perf YTD159.34%
Dividend- P/FCF- EPS past 5Y- ROI-32.00% 52W High-0.59% Beta-
Dividend %- Quick Ratio25.70 Sales past 5Y- Gross Margin- 52W Low209.91% ATR0.25
Employees72 Current Ratio25.70 Sales Q/Q- Oper. Margin- RSI (14)60.21 Volatility0.62% 0.52%
OptionableYes Debt/Eq0.00 EPS Q/Q-7.00% Profit Margin- Rel Volume0.21 Prev Close47.35
ShortableYes LT Debt/Eq0.00 EarningsNov 06 Payout- Avg Volume1.16M Price47.20
Recom3.00 SMA200.73% SMA506.31% SMA20054.58% Volume246,022 Change-0.32%
Nov-08-19Downgrade Stifel Buy → Hold
Nov-08-19Downgrade Guggenheim Buy → Neutral
Jul-29-19Downgrade Raymond James Strong Buy → Mkt Perform
Jun-21-19Initiated Robert W. Baird Outperform
May-22-19Initiated SVB Leerink Outperform $33
Feb-08-19Initiated Stifel Buy $55
Oct-10-18Upgrade Raymond James Outperform → Strong Buy
Jul-20-18Initiated BMO Capital Markets Outperform $20
Jan-18-18Resumed Credit Suisse Outperform $16
Sep-15-17Initiated RBC Capital Mkts Outperform $21
Dec-08-19 03:18PM  Hedge Funds Have Never Been This Bullish On Ra Pharmaceuticals, Inc. (RARX) Insider Monkey
Dec-05-19 10:02AM  Ra Pharmaceuticals Begins Phase II Study on Autoimmune Drug Zacks
Dec-04-19 07:00AM  Ra Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM Business Wire
Dec-03-19 05:45PM  Moore Kuehn, PLLC Encourages Liberty Property Trust (LPT), Proteon Therapeutics (PRTO), Ra Pharmaceuticals (RARX), Carolina Trust BancShares (CART), and Highlands Bankshares (HLND) Investors to Contact Firm PR Newswire
Nov-26-19 12:15PM  Merger Investigation Alert: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - IPHS, FOMX, RARX ACCESSWIRE
Nov-25-19 11:30PM  Rigrodsky & Long, P.A. Files Class Action Suit Against Ra Pharmaceuticals, Inc. GlobeNewswire
Nov-23-19 11:07AM  Shareholder Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies Is Fair to Shareholders RARX, IPHS, CISN, LPT GlobeNewswire
Nov-22-19 02:15PM  INVESTOR ALERT: Monteverde & Associates PC Continues its Investigation on the Following Transaction ACCESSWIRE
Nov-21-19 05:00PM  RARX, WMGI, IBKC: Monteverde & Associates PC Continues Legal Inquiry Regarding the Buyout ACCESSWIRE
Nov-20-19 03:47PM  Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of United Community, Highlands, MB Bancorp, and Ra Pharmaceuticals on behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire
Nov-19-19 04:25PM  SHAREHOLDER ALERT: Monteverde & Associates PC Reminds Investors of its Ongoing Inquiry Regarding the Acquisition ACCESSWIRE
Nov-16-19 09:39AM  Shareholder Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies Is Fair to Shareholders  WLH, CISN, RARX, TECD GlobeNewswire
Nov-15-19 05:05PM  SHAREHOLDER ALERT: WeissLaw LLP Reminds HLND, TNCB, RARX, and IPHS Shareholders About Its Ongoing Investigations GlobeNewswire
Nov-11-19 03:37PM  Shareholder Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies is Fair to Shareholders IPHS, INXN, RARX, VSI GlobeNewswire
Nov-07-19 04:55PM  SHAREHOLDER ALERT: Monteverde & Associates PC Continues Legal Inquiry Regarding the Buyout ACCESSWIRE
07:00AM  Ra Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update Business Wire
Nov-04-19 03:53PM  Merger Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies is Fair to Shareholders VSI, RARX, SRCI, UCFC GlobeNewswire
02:55PM  Lifshitz & Miller LLP Announces Investigation of Achillion Pharmaceuticals, Inc., Anixter International Inc., Central European Media Enterprises Ltd., Digital Realty Trust, Inc., Fitbit, Inc., MutualFirst Financial, Inc., and Ra Pharmaceuticals Inc. PR Newswire
02:27PM  MERGER ALERT RARX, EMPK, and CETV: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies GlobeNewswire
Nov-01-19 06:26PM  SHAREHOLDER ALERT: WeissLaw LLP Reminds HLND, TNCB, and RARX Shareholders About Its Ongoing Investigations GlobeNewswire
02:10PM  Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies Is Fair to Shareholders RARX, ACHN, IPHS, CISN GlobeNewswire
Oct-29-19 03:02PM  SHAREHOLDER ALERT: WeissLaw LLP Reminds HLND, TNCB, ACHN, RARX Shareholders About Its Ongoing Investigations GlobeNewswire
Oct-28-19 08:06PM  Is Ra Pharmaceuticals, Inc. (RARX) Going To Burn These Hedge Funds ? Insider Monkey
12:30PM  MERGER ALERT ACHN, RARX, and IPHS: Levi & Korsinsky, LLP Notifies Investors of Investigations Concerning the Sale of these Companies GlobeNewswire
Oct-25-19 08:30PM  Stock Holdings in Callon Petroleum, Ra Pharmaceuticals, and More Barrons.com
Oct-24-19 02:06PM  SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts GlobeNewswire
09:45AM  SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh Llp Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders - RARX, ROAN, VSI ACCESSWIRE
Oct-23-19 04:27PM  MERGER ALERT RARX, DOVA, and SEMG: Levi & Korsinsky, LLP Notifies Investors of Investigations Concerning the Sale of these Companies GlobeNewswire
Oct-22-19 03:07PM  Merger Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders IPHS, ACHN, RARX, TSG GlobeNewswire
Oct-21-19 06:50PM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Ra Pharmaceuticals, Inc. (NASDAQ GS: RARX) ACCESSWIRE
Oct-19-19 10:30AM  ACT NOW: Monteverde & Associates PC Continues Legal Inquiry Regarding the Buyout ACCESSWIRE
Oct-18-19 12:00PM  SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Continues To Investigate Whether The Sale Of These Companies Is Fair To Shareholders - RARX, DOVA, ACHN ACCESSWIRE
Oct-17-19 05:35PM  READ NOW: Monteverde & Associates PC Continues Investigations on the Following Merger ACCESSWIRE
01:56PM  RARX, ROAN, and FCSC SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts GlobeNewswire
Oct-16-19 06:18PM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Ra Pharmaceuticals, Inc. (NASDAQ GS: RARX) ACCESSWIRE
01:12PM  MERGER ALERT RARX, DOVA, and ROAN: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies GlobeNewswire
Oct-15-19 10:12AM  Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders RARX, PGNX, TSG, ROAN GlobeNewswire
Oct-14-19 06:02PM  RA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ra Pharmaceuticals, Inc. - RARX Business Wire
Oct-11-19 04:19PM  STOCKHOLDER ALERT: Monteverde & Associates PC is Investigating the Following Merger PR Newswire
12:23PM  A Look At Benzinga Pro's Most-Searched Tickers For October 11, 2019 Benzinga
10:33AM  Company News For Oct 11, 2019 Zacks
Oct-10-19 04:22PM  This Biotech Stock Just Doubled After Snagging A $2.1 Billion Takeover Deal Investor's Business Daily +101.10%
03:09PM  4 Stocks With More Than 20% Price Increases on Thursday GuruFocus.com
02:52PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Ra Pharmaceuticals, Inc. to UCB S.A. is Fair to Shareholders GlobeNewswire
02:34PM  Ra Pharma acquired for $2.1B by Belgian firm that vows to grow in Boston American City Business Journals
02:24PM  Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) on Behalf of Ra Pharma Shareholders and Encourages Ra Pharma Investors to Contact the Firm PR Newswire
02:21PM  SHAREHOLDER ALERT: WeissLaw LLP Investigates Ra Pharmaceuticals, Inc. PR Newswire
01:15PM  RA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout ACCESSWIRE
12:54PM  Ra Pharmaceuticals Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Ra Pharmaceuticals, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm RARX GlobeNewswire
12:31PM  Ra Pharma Stock Doubles On $2.5B Buyout Deal With Belgian Biopharma UCB Benzinga
08:12AM  Ra Pharma (RARX) Alert: Johnson Fistel Investigates Proposed Sale of Ra Pharmaceuticals; Is $48 a Fair Price? PR Newswire
07:31AM  The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO Benzinga
07:18AM  Belgium's UCB to acquire Ra Pharma in cash deal valued at about $2.5 billion MarketWatch
07:00AM  UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases PR Newswire
06:53AM  [video]RA Pharmaceuticals Soars on Deal to Be Acquired for $2.1 Billion TheStreet.com
02:28AM  UCB to acquire Ra Pharmaceuticals in $2.1 billion deal MarketWatch
02:15AM  UPDATE 1-Belgium's UCB to buy Ra Pharmaceuticals in $2.1 bln cash deal Reuters
01:22AM  Belgium's UCB to buy Ra Pharmaceuticals for $2.1 bln Reuters
01:22AM  UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases Business Wire
Oct-02-19 07:00AM  Ra Pharmaceuticals Announces Dosing of First Patient in Global Phase 3 Pivotal Study of Zilucoplan for gMG Business Wire
Sep-18-19 07:00AM  Ra Pharmaceuticals Announces Selection for the First ALS Platform Trial by the Sean M. Healey & AMG Center for ALS at Mass General Business Wire
Sep-04-19 07:00AM  Ra Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for Zilucoplan for the Treatment of Myasthenia Gravis Business Wire
Aug-21-19 07:00AM  Ra Pharmaceuticals Earns Clinical Development Milestone for Oral Macrocyclic Peptide Candidate Targeting Cardiovascular Indication Under Agreement with Merck Business Wire
Aug-07-19 07:00AM  Ra Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update Business Wire
Jul-26-19 10:44AM  Ra Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Jul-23-19 08:09PM  Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock Business Wire -6.67%
07:26AM  The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation Benzinga
Jul-22-19 05:29PM  Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire +7.34%
Jul-16-19 07:00AM  Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Zilucoplan Business Wire
Jun-19-19 10:40AM  Hedge Funds Have Never Been This Bullish On Ra Pharmaceuticals, Inc. (RARX) Insider Monkey
Jun-04-19 07:00AM  Ra Pharmaceuticals Announces Expansion of Neuromuscular Portfolio with Clearance of IND Application for Zilucoplan for the Treatment of Immune-Mediated Necrotizing Myopathy Business Wire
May-28-19 07:00AM  Ra Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
May-14-19 07:00AM  Ra Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
May-09-19 07:19PM  Hedge Funds Have Never Been This Bullish On Ra Pharmaceuticals, Inc. (RARX) Insider Monkey
07:00AM  Ra Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update Business Wire
May-07-19 07:00AM  Ra Pharmaceuticals Announces Positive gMG Phase 2 and Open-Label, Long-Term Extension Data at the 2019 AAN Annual Meeting Business Wire
Apr-24-19 06:30AM  Ra Pharmaceuticals Presents Pre-Clinical Data for Zilucoplan XR at the 6th Annual Peptides Congress Business Wire
Apr-10-19 02:34PM  Ra Pharmaceuticals Closes End-of-Phase 2 Interaction with FDA Zacks
Apr-09-19 07:00AM  Ra Pharmaceuticals Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Pivotal Phase 3 gMG Study Business Wire
Apr-01-19 04:05PM  Ra Pharmaceuticals Announces Acceptance of gMG Phase 2 and Open-Label, Long-Term Extension Data for Emerging Science Dual Presentation at the 2019 AAN Annual Meeting Business Wire -7.19%
Mar-07-19 07:31AM  Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update Business Wire +13.87%
Mar-04-19 07:00AM  Ra Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference Business Wire
Feb-28-19 07:00AM  Ra Pharmaceuticals Supports 12th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases Business Wire
Feb-25-19 03:25PM  5 Clinical-Stage Biotech Stocks to Buy InvestorPlace
Feb-21-19 07:00AM  Ra Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference Business Wire +5.50%
Dec-20-18 12:27PM  Hedge Funds Are Betting On Ra Pharmaceuticals, Inc. (RARX) Insider Monkey
Dec-11-18 06:32PM  Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock Business Wire -9.70%
08:22AM  The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings Benzinga
Dec-10-18 04:32PM  Why Nutrisystem, Xperi, and Ra Pharmaceuticals Jumped Today Motley Fool +7.05%
04:01PM  Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
03:26PM  Here's Why Ra Pharmaceuticals Inc. Is Soaring Today Motley Fool
01:54PM  Ra Pharma Shares Rally: What You Need To Know Benzinga
07:00AM  Ra Pharmaceuticals Announces Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia Gravis Business Wire
Dec-06-18 07:30AM  Ra Pharmaceuticals Receives Development Milestone Payment Under Agreement with Merck Business Wire
Nov-15-18 07:30AM  Ra Pharmaceuticals Elects Bo Cumbo to Board of Directors Business Wire +12.93%
Nov-07-18 05:17PM  ADDING and REPLACING Ra Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update Business Wire
Nov-06-18 07:30AM  Ra Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Sep-28-18 10:07AM  Can the Rally in Ra Pharmaceuticals (RARX) Shares Continue? Zacks
Sep-26-18 07:30AM  Ra Pharma Announces Positive Results from Phase 1b Pharmacokinetic Study of Zilucoplan (RA101495 SC) in Patients with Renal Impairment Business Wire +6.20%
Sep-25-18 04:05PM  Ra Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference Business Wire
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Farzaneh-Far RaminChief Medical OfficerNov 15Option Exercise5.6010,59559,33217,727Nov 18 05:08 PM
Farzaneh-Far RaminChief Medical OfficerNov 15Sale46.6610,595494,3197,132Nov 18 05:08 PM
Read SimonChief Scientific OfficerNov 14Option Exercise2.8710,00028,70016,234Nov 18 05:07 PM
Read SimonChief Scientific OfficerNov 14Sale46.6810,000466,8086,234Nov 18 05:07 PM
Ricardo AlonsoSee RemarksOct 17Sale46.702,285106,7106,858Oct 17 08:11 PM
Read SimonChief Scientific OfficerOct 16Option Exercise2.8710,00028,70016,234Oct 17 07:00 PM
Read SimonChief Scientific OfficerOct 16Sale46.8710,000468,7266,234Oct 17 07:00 PM
Farzaneh-Far RaminChief Medical OfficerOct 15Option Exercise5.6010,59559,33217,727Oct 17 07:00 PM
Farzaneh-Far RaminChief Medical OfficerOct 15Sale46.8910,595496,7697,132Oct 17 07:00 PM
Farzaneh-Far RaminChief Medical OfficerSep 16Option Exercise5.6010,59559,33217,727Sep 16 06:44 PM
Farzaneh-Far RaminChief Medical OfficerSep 16Sale25.2610,595267,6757,132Sep 16 06:44 PM
Read SimonChief Scientific OfficerSep 12Option Exercise2.8710,00028,70016,234Sep 16 06:43 PM
Read SimonChief Scientific OfficerSep 12Sale25.4110,000254,0506,234Sep 16 06:43 PM
Read SimonChief Scientific OfficerAug 23Option Exercise2.8710,00028,70016,234Aug 27 06:01 PM
Farzaneh-Far RaminChief Medical OfficerAug 23Option Exercise5.6010,59559,33217,727Aug 27 06:01 PM
Farzaneh-Far RaminChief Medical OfficerAug 23Sale27.7710,595294,2267,132Aug 27 06:01 PM
Read SimonChief Scientific OfficerAug 23Sale27.7710,000277,7036,234Aug 27 06:01 PM
Ricardo AlonsoSee RemarksAug 23Sale27.892,28563,7409,143Aug 27 06:00 PM
Read SimonChief Scientific OfficerJul 17Option Exercise2.8710,00028,70016,234Jul 18 07:04 PM
Read SimonChief Scientific OfficerJul 17Sale32.9510,000329,4796,234Jul 18 07:04 PM
Farzaneh-Far RaminChief Medical OfficerJul 15Option Exercise5.6010,59559,33217,727Jul 16 07:15 PM
Farzaneh-Far RaminChief Medical OfficerJul 15Sale33.1010,595350,6477,132Jul 16 07:15 PM
Ricardo AlonsoSee RemarksJun 21Sale23.722,85767,78211,428Jun 25 04:16 PM
Read SimonChief Scientific OfficerJun 18Option Exercise2.8710,00028,70016,234Jun 19 09:03 PM
Read SimonChief Scientific OfficerJun 18Sale22.2510,000222,4676,234Jun 19 09:03 PM
Farzaneh-Far RaminChief Medical OfficerJun 17Option Exercise5.6010,59559,33217,727Jun 19 09:03 PM
Farzaneh-Far RaminChief Medical OfficerJun 17Sale21.8410,595231,3847,132Jun 19 09:03 PM